SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay
Michael J. Peluso, Saki Takahashi, Jill Hakim, J. Daniel Kelly, Leonel Torres, Nikita S. Iyer, Keirstinne Turcios, Owen Janson, Sadie E. Munter, Cassandra Thanh, Christopher C. Nixon, Rebecca Hoh, Viva Tai, Emily A. Fehrman, Yanel Hernandez, Matthew A. Spinelli, Monica Gandhi, Mary-Ann Palafox, Ana Vallari, Mary A. Rodgers, John Prostko, John Hackett Jr., Lan Trinh, Terri Wrin, Christos J. Petroplolous, Charles Y. Chiu, Philip J. Norris, Clara DiGermanio, Mars Stone, Michael P. Busch, Susanna K. Elledge, Xin X. Zhou, James A. Wells, Albert Shu, Theodore W. Kurtz, John E. Pak, Wesley Wu, Peter D. Burbelo, Jeffrey I. Cohen, Rachel L. Rutishauser, Jeffrey N. Martin, Steven G. Deeks, Timothy J. Henrich, Isabel Rodriguez-Barraquer, Bryan Greenhouse
medRxiv 2021.03.03.21251639; doi: https://doi.org/10.1101/2021.03.03.21251639